| Name | Title | Contact Details |
|---|
Richelieu is Canadas leading distributor, importer, and manufacturer of specialty hardware and complementary products - and also ranks among the top players in its specialty in North America. We are the leading driver of worldwide innovations in functional and decorative hardware. We provide manufacturers and retailers with a UNIQUE mix of more than 130,000 different items in a host of categories: decorative hardware · kitchen accessories · lighting systems · functional and decorative mouldings · functional hardware · ergonomic workstations · finishing and decorating products · high-pressure laminates · veneer sheets and edgebanding products · screws and fasteners... We take pride in serving more than 110,000 customers across North America, in two major markets: * Manufacturers o Kitchen and bathroom cabinet manufacturers o Home and office furniture manufacturers o Residential and commercial woodworking industry, etc. * Retailers o Purchasing groups o Small and medium-sized hardware stores o Renovation superstores 113 distribution centers in North America. Some 3,000 people work throughout the network, more than half are specialized in sales and marketing, so as to provide our extensive base of loyal customers with first-class service. Richelieu Hardware Ltd. is a public company listed on the Toronto Stock Exchange (TSX) under the ticker symbol RCH.
Elementary is a company specializing in advanced machine vision inspection, utilizing AI and automation to enhance manufacturing processes. Founded in mid-2017 by experienced professionals from various sectors, the company aims to develop a new generation of manufacturing products that rely on computer vision and AI. Their platform automates traceability scans and integrates AI, machine vision, and automation into production lines. This approach focuses on improving quality, traceability, and root cause analyses, making manufacturing processes more efficient. Elementary emphasizes a human-in-the-loop strategy, enhancing collaboration between humans and machines to optimize working conditions and outcomes. Based in Los Angeles, California, Elementarys team includes roboticists, computer scientists, designers, and engineers. The company has attracted significant funding, including a $30 million Series B round led by Tiger Global, to support its innovative solutions in manufacturing. Their technology is utilized by notable clients across various industries, including Toyota in the automotive sector.
Giupedi Utilizes Generative AI for High Quality Legal Client Acquisition Giupedi has created a unique Platform for advertising and marketing in the Workers Compensation, Medical Malpractice, and Personal Injury litigation industry. Prospective clients are empowered to make decisions and attorney selections in a manner that utilizes Generative AI and Secure Information Sharing.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.